drugset / Trial / NCT00888511
Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Phase 2
Completed
15 enrolled
Olfred Hansen
Aalborg University Hospital · collabAarhus University Hospital · collabCopenhagen University Hospital at Herlev · collabNaestved Hospital · collabOdense University Hospital · collabRigshospitalet, Denmark · collab
NaSingle-groupOpen-labelTreatment
Summary
The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).
Timeline
- Start
- 2009-05
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | — |